$4.32
+0.24(6.02%)
Mkt Cap $59M
$1.83
$4.59
52-Week Range
At a Glance
AI-generatedOnKure Therapeutics, Inc.
8-K
OnKure Therapeutics entered into a $150 million private placement to fund its next-generation PI3Kα pan-mutant programs and appointed a new director designated by the lead investor.$59M
Market Cap
—
Revenue
-$60M
Net Income
Employees46
Fundamentals
How The Business Makes Money
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001637715
ISINUS68277Q1058
Phone720 307 2892
Address6707 Winchester Circle, Boulder, CO, 80301, US
SEC EDGAR